Publication
In vivo antitumoral efficacy of PhAc-ALGP-doxorubicin, an enzyme-activated doxorubicin prodrug, in patient-derived soft tissue sarcoma xenograft models
Journal Contribution - Journal Article
We evaluated the efficacy of PhAc-ALGP-doxorubicin (ALGP-doxo), a prodrug metabolized to doxo by peptidases present in tumor cells and/or tumor microenvironment, in a synovial sarcoma (SynSa) and two dedifferentiated liposarcoma (DDLPS) patient-derived xenograft models. Sixty-eight mice were engrafted bilaterally with human DDLPS or SynSa and randomized to control, doxo or ALGP-doxo treatment, which were administered using an intraperitoneal minipump. Tumor volume measurement, histopathology and Western blotting were used to assess treatment efficacy. Tumor regrowth was evaluated in a subset of mice over a period of two weeks after treatment cessation.
While tumor volume in the control and doxo groups increased steadily, ALGP-doxo caused tumor volume stabilization in the DDLPS xenografts and significant tumor shrinkage in the SynSa model, continuing after treatment cessation. A significant decrease in proliferation and increase in apoptosis compared to control and doxo was observed during and after treatment with ALGP-doxo in all models.
In conclusion, ALGP-doxo shows considerably higher antitumoral efficacy compared to doxo in all patient-derived xenograft models tested. Administration of a 30-40 fold higher dose of ALGP-doxo than doxo is tolerated without significant adverse events. These results warrant further testing of this prodrug in anthracycline-sensitive and -resistant models of soft tissue sarcoma.